Home › NCT05024175

Long-term Follow-up of Subjects Treated With CAR T Cells

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

Subjects will be asked to participate leading up to the last DF/HCC corresponding main study visit.

Subjects meeting the following criteria are eligible for study participation:

* Provision of voluntary written informed consent by subject
* CAR T cells were administered in DF/HCC IRB corresponding main study

Exclusion Criteria:

Subjects meeting the following criterion are to be excluded from study participation:

\- Subject unable to comply with study requirements

About the study

This is a single site, non-randomized, open-label, long-term safety and efficacy follow-up study for Phase 1 studies that evaluate the safety and efficacy of CAR T cells: NCT05660369 (DF/HCC# 22-175) and NCT06026319 (DF/HCC# 23-474).

What is being tested

• Disease assessments (diagnostic test)
• Tumor Biopsy (procedure)
• Blood test (diagnostic test)

Sponsor: Marcela V. Maus, M.D.,Ph.D. · Participants: 45 · Started: Aug 7, 2023

Contact the study team

• Matthew J Frigault, MD · Phone: 617-643-6175

Official record on ClinicalTrials.gov — NCT05024175

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.